Department of Healthcare Quality Assessment, The University of Tokyo, Japan (R.N., S.N., H.K., H.Y., H.M., S.K.).
Shizuoka Graduate University of Public Health, Japan (R.N., S.N., H.K., S.S., E.N., H.Y., Y.M., H.M., S.K.).
Circ Cardiovasc Qual Outcomes. 2024 Aug;17(8):e010642. doi: 10.1161/CIRCOUTCOMES.123.010642. Epub 2024 Jun 19.
The increasing prevalence of frailty has gained considerable attention due to its profound influence on clinical outcomes. However, our understanding of the progression of frailty and long-term clinical outcomes in older individuals with atrial fibrillation remains scarce.
Using data from 2012 to 2018 from a comprehensive claims database incorporating primary and hospital care records in Shizuoka, Japan, we selected patients aged ≥65 years with atrial fibrillation who initiated oral anticoagulant therapy. The trajectory of frailty was plotted using Sankey plots, illustrating the annual changes in their frailty according to the electronic frailty index during a 3-year follow-up after oral anticoagulant initiation, along with the incidence of clinical adverse outcomes. For deceased patients, we assessed their frailty status in the year preceding their death.
Of 6247 eligible patients (45.1% women; mean age, 79.3±8.0 years) at oral anticoagulant initiation, 7.7% were categorized as fit (electronic frailty index, 0-0.12), 30.1% as mildly frail (>0.12-0.24), 35.4% as moderately frail (>0.24-0.36), and 25.9% as severely frail (>0.36). Over the 3-year follow-up, 10.4% of initially fit patients transitioned to moderately frail or severely frail. Conversely, 12.5% of severely frail patients improved to fit or mildly frail. Death, stroke, and major bleeding occurred in 23.4%, 4.1%, and 2.2% of patients, respectively. Among the mortality cases, 74.8% (N=1183) and 3.5% (N=55) had experienced moderately or severely frail and either a stroke or major bleeding in the year preceding their death, respectively.
In a contemporary era of atrial fibrillation management, a minor fraction of older patients on oral anticoagulants died following a stroke or major bleeding. However, their frailty demonstrated a dynamic trajectory, and a substantial proportion of death was observed after transitioning to a moderately or severely frail state.
衰弱症的患病率不断上升,引起了广泛关注,因为它对临床结果有深远影响。然而,我们对老年房颤患者衰弱症的进展和长期临床结局的了解仍然有限。
利用日本静冈县综合索赔数据库(包含初级和医院护理记录)2012 年至 2018 年的数据,我们选择了年龄≥65 岁、开始口服抗凝治疗的房颤患者。使用 Sankey 图描绘衰弱轨迹,根据口服抗凝剂治疗开始后 3 年的电子虚弱指数,显示他们在 3 年内每年的虚弱变化,并显示临床不良结局的发生率。对于死亡患者,我们评估了他们在死亡前一年的虚弱状态。
在符合条件的 6247 例患者(45.1%为女性;平均年龄 79.3±8.0 岁)中,7.7%为健康(电子虚弱指数为 0-0.12),30.1%为轻度虚弱(>0.12-0.24),35.4%为中度虚弱(>0.24-0.36),25.9%为重度虚弱(>0.36)。在 3 年的随访期间,最初健康的患者中有 10.4%转为中度或重度虚弱。相反,12.5%的重度虚弱患者恢复到健康或轻度虚弱。死亡、卒中和大出血分别发生在 23.4%、4.1%和 2.2%的患者中。在死亡病例中,74.8%(N=1183)和 3.5%(N=55)在死亡前一年经历过中度或重度虚弱,并且发生了卒中和大出血。
在当前的房颤管理时代,少数服用口服抗凝剂的老年患者在发生卒中和大出血后死亡。然而,他们的虚弱状况呈动态轨迹,在过渡到中度或重度虚弱状态后,大量患者死亡。